NCT07687186 Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
| NCT ID | NCT07687186 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Tasly Pharmaceutical Group Co., Ltd |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 636 participants |
| Start Date | 2026-06-22 |
| Primary Completion | 2028-06-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 636 participants in total. It began in 2026-06-22 with a primary completion date of 2028-06-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial will evaluate the efficacy and safety of Qishen Yiqi Dripping Pills in treatment of Chronic Heart Failure with reduced ejection fraction resorted from Coronary Heart Disease (Syndrome of Qi Deficiency with Blood Stasis).
Eligibility Criteria
Inclusion Criteria: * Male or female subjects aged ≥ 18 years and ≤80 years when signing the informed consent form. * Conformed to the diagnostic criteria of coronary heart disease and chronic heart failure. * Conformed to the TCM syndrome differentiation standard of chronic heart failure syndrome of Qi deficiency and blood stasis. * NYHA Functional Classification Ⅱ-Ⅲ. * Left ventricular ejection fraction (LVEF) \< 45% (modified two-plane Simpson method). * Received standardized drug therapy for chronic heart failure at least 2 weeks before randomization without adjustment of dose, and did not receive intravenous therapy (vasoactive drugs, diuretics) within 2 weeks. * Voluntarily participate in the clinical trial, sign the informed consent form, and be able to understand and comply with the trial procedures. Exclusion Criteria: * Heart failure caused by other cardiovascular diseases, such as infectious endocarditis, cardiac amyloidosis, genetic abnormalities (genetic factors related to hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy), valve and cardiac structure abnormalities (moderate or above aortic valve stenosis, other severely narrowed or incompetent heart valves, congenital heart disease), constrictive pericarditis, moderate or large pericardial effusion. * Heart failure caused by other non-cardiovascular diseases, such as severe infection, autoimmune diseases, tumor metastasis or infiltration, pulmonary heart disease, primary pulmonary hypertension, secondary severe pulmonary hypertension, kidney diseases, liver diseases, cardiac toxic injury (cardiotoxic drugs such as anti-tumor drugs, alcoholic cardiomyopathy). * Within 3 months before receiving the investigational drug, had acute myocardial infarction, undergone revascularization \[percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG)\] treatment, undergone left ventricular assist device \[cardiac resynchronization therapy (CRT), implantable cardioverter defibrillator (ICD), etc.\] treatment, undergone cardiac surgery (left ventricular reconstruction, heart transplantation, etc.) treatment, had acute cerebrovascular events (acute ischemic stroke, cerebral hemorrhage, transient ischemic attack). * Planned to undergo revascularization (PCI, CABG, etc.) or left ventricular assist device (CRT, ICD, etc.) treatment, or other cardiac surgery during the trial. * Had severe, progressive, or uncontrolled diseases, including but not limited to immune system, endocrine system, blood system, urinary system, liver and gallbladder system, respiratory system, nervous system, mental system, cardiovascular system, gastrointestinal system or infectious diseases, malignant tumors, etc. * Had uncontrolled hypertension (after antihypertensive treatment, systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg), or had hypotension (systolic blood pressure \< 80 mmHg and/or diastolic blood pressure \< 50 mmHg). * Severe arrhythmias such as ventricular tachycardia, second-degree type II or above sinus or atrioventricular conduction block without pacemaker treatment. * Abnormal liver function tests \[alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2 times the upper limit of the normal value of the laboratory in this center\], or abnormal renal function tests \[serum creatinine (Cr) \> 1.5 times the upper limit of the normal value of the laboratory\]. * Glycated hemoglobin (HbA1c) ≥ 9.0%. * Hemoglobin (Hb) \< 90 g/L. * Serum potassium concentration \> 5.5 mmol/L. * Need to take anticoagulants, dose stable for less than 1 month, or INR \> 3.0. * Need to take antiplatelet drugs, dose stable for less than 1 month, and platelets lower than the lower limit of the normal value. * Allergic to the Chinese medicine formula of Qishen YiQi (QSYQ) Dripping Pills (Astragalus membranaceus, Salvia miltiorrhiza, Panax notoginseng, and Dalbergia odorifera), or allergic to other Chinese medicines with the same ingredients or the same therapeutic functions. * Within 2 weeks before randomization, had received drugs affecting exercise tolerance assessment (such as trimetazidine, renozine, coenzyme Q10, levocarnitine, and androgens) or Chinese medicine preparations with the same ingredients or the same therapeutic functions. * Had absolute contraindications for the 6-minute walk test or was unable to complete the 6-minute walk test. * Had participated in other interventional drug clinical trials within 1 month before screening. * Pregnant or lactating women, or had a pregnancy plan or could not take effective contraceptive measures from the screening period to the end of the trial and within 1 month after the last administration. * Any other circumstances where other researchers deem it inappropriate for a participant to take part in the trial, such as if the participant has potential issues with compliance, is unable to complete all the examinations and evaluations as per the protocol requirements, or if there are uncontrollable risks associated with participating in the trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07687186 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07687186 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 636 participants.
Is NCT07687186 currently recruiting?
Yes, NCT07687186 is actively recruiting participants. Contact the research team at liurui2@tasly.com for enrollment information.
Where is the NCT07687186 trial being conducted?
This trial is being conducted at Bozhou, China, Hefei, China, Suzhou, China, Beijing, China and 11 additional locations.
Who is sponsoring the NCT07687186 clinical trial?
NCT07687186 is sponsored by Tasly Pharmaceutical Group Co., Ltd. The trial plans to enroll 636 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.